Galectin Therapeutics misses Q1 EPS by $0.20, shares rise, StockNews downgrades to "sell".

Galectin Therapeutics reported a $0.20 EPS miss for Q1, with shares rising despite the shortfall. The clinical-stage biopharmaceutical firm is developing therapies for fibrotic and cancer diseases. Its lead product, belapectin (GR-MD-02), is in Phase 2b/3 trials for NASH cirrhosis and Phase 2 for other diseases. StockNews.com downgraded the company from "hold" to "sell" on July 18.

Articles

Modern Readers

Markets Daily

The Enterprise Leader

-- show less --

Further Reading

Related Stories